Exhibit 99.1


Misonix Reports Fiscal Year 2017

Financial Results


For Immediate Release


Corporate Contact Investor Contact
Joe Dwyer Joe Diaz
Misonix, Inc. Lytham Partners
631-927-9113 602-889-9700
jdwyer@misonix.com mson@lythampartners.com


FARMINGDALE, NY – August 22, 2017 --

Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today financial results for the fourth quarter and fiscal year ended June 30, 2017.


Financial Highlights for the Fourth Quarter and the Full Year:


Revenue for fiscal year 2017 was $27.3 million, an increase of 18% compared with $23.1 million in fiscal 2016. For the fourth quarter, net sales increased 23% to $7.9 million compared with $6.4 million in the fourth quarter of fiscal 2016.
Domestic sales in fiscal year 2017 increased 26% to $16.5 million versus $13.1 million in fiscal 2016. For the fourth quarter of fiscal 2017, domestic sales increased 18% to $4.4 million compared with $3.8 million in the fourth quarter of 2016.
Consumables sales in the United States increased 32% to $14.9 million for fiscal year 2017 compared with $11.3 million in fiscal 2016.
The gross profit margin for the fiscal year was 69.9% primarily from a strong mix of higher margin consumables, compared to 66.9% in fiscal year 2016. Fourth quarter gross profit margin was 69.9% versus 68.0% in the fourth quarter of fiscal 2016.
For the fiscal year, operating expenses increased by $4.4 million to $25.7 million driven in part by professional fees relating to the recently completed internal investigation, along with higher sales commissions related to increased sales volume.
For fiscal year 2017, the Company reported a net loss of $1.7 million, or $(0.20) per diluted share, compared with a net loss of $1.2 million, or $(0.15) per diluted share, in fiscal year 2016.
At June 30, 2017, the Company had cash of $11.6 million with no long-term debt.


Stavros Vizirgianakis, president and chief executive officer of Misonix, said, “We concluded fiscal 2017 on a strong note with fourth quarter revenue increasing 23%, and 18% for the full year as our recurring revenue business model continues to gain traction. Consumables sales, which we define as recurring revenue, accounted for approximately 75% of total sales. Gross margin for the fiscal year was 69.9% up from 66.9% in the previous year.


“Our U.S. business, which we believe offers the best opportunity for growth, grew 26% on a year-over-year basis and accounted for 60% of total revenue. We are making sustainable progress in reigniting the Misonix growth engine.





“One of the contributing factors in the growth of fiscal 2017 revenue has been the addition of new Clinical Sales Specialists to support the sales activities of our distribution channel. Although the second half of the fiscal year is traditionally the strongest for our business, the additional support provided to our distributors generated strong double-digit revenue increases in both the third and fourth quarters of fiscal 2017. We are pleased with the progress achieved to this point.”


Mr. Vizirgianakis continued, “On the international front, we are making necessary changes in distributors and personnel to operate the business more efficiently. Going forward, we will focus on contracting with in-country distributors in the key markets where we believe we can build sustainably growing operations that adhere to single-use of consumable products in surgical procedures.


“As we move ahead, we are working to create a new results-oriented culture within the Company. We have simplified our sales compensation plan with the goal of getting everyone on equal footing and pursuing common goals. In fiscal 2017 Misonix consumables products were used in more than 50,000 surgical procedures worldwide. We have set an aggressive goal of having Misonix consumables products utilized in 100,000 annual surgical procedures worldwide within the next three years. We are dedicated to achieving that goal.


“We enter the new fiscal year with a strong cash position, in excess of $11 million, and no long-term debt. We look forward to the opportunities ahead in fiscal 2018.”


Conference Call

The Company has scheduled a conference call for Tuesday, August 22, 2017, at 4:30 pm ET to review the results.


Interested parties can access the conference call by dialing (844) 861-5497 or (412) 317-6579 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company’s website at www.misonix.com.


A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10111207. A webcast replay will be available in the Investor Relations section of the Company’s website at www.misonix.com for 30 days.


Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, the impact of the pending investigation by the Department of Justice and Securities Exchange Commission, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.





MISONIX INC. and Subsidiaries
Consolidated Balance Sheets

   June 30,
   June 30,
Current assets:          
Cash and cash equivalents  $11,557,071   $9,049,327 
Accounts receivable, less allowance for doubtful accounts of  $96,868 and $96,868, respectively   5,133,389    3,869,427 
Inventories, net   4,992,434    5,822,935 
Prepaid expenses and other current assets   918,899    530,564 
Total current assets   22,601,793    19,272,253 
Property, plant and equipment, net of accumulated amortization and depreciation of $7,794,580 and $6,976,282, respectively   3,730,203    2,492,815 
Patents, net of accumulated amortization of $995,568 and $885,394, respectively   719,136    604,916 
Goodwill   1,701,094    1,701,094 
Intangible and other assets   282,876    266,603 
Deferred income tax   4,334,547    3,394,690 
Total assets  $33,369,649   $27,732,371 
Liabilities and shareholders’ equity          
Current liabilities:          
Accounts payable  $1,861,228   $1,402,797 
Accrued expenses and other current liabilities   3,346,138    1,887,337 
Total current liabilities   5,207,366    3,290,134 
Deferred lease liability   9,354    9,262 
Deferred income   13,087    31,685 
Total liabilities   5,229,807    3,331,081 
Commitments and contingencies          
Shareholders’ equity:          
Common stock, $.01 par value-shares authorized 20,000,000; 9,357,166 and 7,948,234 shares issued and 9,357,166 and 7,809,385 outstanding in each period, respectively   93,572    79,482 
Additional paid-in capital   36,808,810    32,502,521 
Accumulated deficit   (8,762,540)   (7,081,361)
Treasury stock, at cost, 0 and 138,849 shares, respectively       (1,099,352)
Total shareholders’ equity   28,139,842    24,401,290 
Total liabilities and shareholders’ equity  $33,369,649   $27,732,371 





MISONIX INC. and Subsidiaries
Consolidated Statements of Operations


   For the years ended
June 30,
   2017   2016   2015 
Net sales  $27,269,963   $23,113,194   $22,204,578 
Cost of goods sold   8,217,439    7,640,626    7,280,276 
Gross profit   19,052,524    15,472,568    14,924,302 
Operating expenses:               
  Selling expenses   14,220,907    12,632,961    9,062,695 
  General and administrative expenses   9,595,206    6,829,516    5,983,623 
  Research and development expenses   1,837,497    1,839,479    1,592,923 
Total operating expenses   25,653,610    21,301,956    16,639,241 
Loss from operations   (6,601,086)   (5,829,388)   (1,714,939)
Other income (expense):               
  Interest income   75    81    75 
  Royalty income and license fees   3,771,610    3,948,757    4,256,321 
  Other   (36,211)   (21,878)   (22,033)
Total other income   3,735,474    3,926,960    4,234,363 
(Loss)/income from continuing operations before income taxes   (2,865,612)   (1,902,428)   2,519,424 
Income tax (benefit)/expense   (1,022,808)   (573,351)   (2,784,632)
Net (loss)/income from continuing operations   (1,842,804)   (1,329,077)   5,304,056 
Discontinued operations:               
Income from discontinued operations net of tax of $0, $0 and $1,127, respectively           17,115 
Gain from sale of discontinued operations net of tax of  $88,375, $93,069 and $0, respectively   161,625    156,931    250,000 
Net income from discontinued operations   161,625    156,931    267,115 
Net (loss)/income  $(1,681,179)  $(1,172,146)  $5,571,171 
Net (loss)/income per share from continuing operations - Basic  $(0.22)  $(0.17)  $0.70 
Net income per share from discontinued operations - Basic   0.02    0.02    0.04 
Net (loss)/income per share - Basic  $(0.20)  $(0.15)  $0.74 
Net (loss)/income per share from continuing operations - Diluted  $(0.22)  $(0.17)  $0.66 
Net income per share from discontinued operations - Diluted   0.02    0.02    0.03 
Net (loss)/income per share - Diluted  $(0.20)  $(0.15)  $0.69 
Weighted average shares - Basic   8,398,778    7,776,949    7,580,450 
Weighted average shares - Diluted   8,398,778    7,776,949    8,094,119 



The following information was filed by Misonix Inc (MSON) on Tuesday, August 22, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Misonix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Misonix Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account